This data note summarizes KFF polling on the U.S. public’s experiences with prescription drug costs, use of GLP-1 medications, and support for policy solutions.

This brief examines issues that may impact consumers, especially those with private insurance, who access drug discounts through TrumpRx.

This brief provides information about several key aspects of the Medicare drug price negotiation program, with a focus on the 2028 implementation year.

The new TrumpRx program relies partly on connecting consumers with discount coupons offered by drugmakers. For insured patients, though, using a coupon can prove dicey.